On Sept. 28, 2022, Moderna announced that the European Medicines Agency had accepted a variation for the evaluation of a 50 ﾵg booster dose of the Omicron-containing bivalent COVID booster candidate, mRNA-1273.222 (Spikevax bivalent Original/Omicron BA.4-5) in adults 12 years and older.

Spikevax bivalent Original/Omicron BA.4-5 is a next-generation bivalent vaccine that contains 25 ﾵg of mRNA-1273 (Spikevax) and 25 ﾵg of a vaccine candidate targeting the Omicron variant of concern (BA.4/BA.5).